Skip to main navigation Skip to search Skip to main content

Randomized phase III trial of erlotinib versus docetaxel as second- Or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and erlotinib lung cancer trial (DELTA)

  • Tomoya Kawaguchi
  • , Masahiko Ando
  • , Kazuhiro Asami
  • , Yoshio Okano
  • , Masaaki Fukuda
  • , Hideyuki Nakagawa
  • , Hidenori Ibata
  • , Toshiyuki Kozuki
  • , Takeo Endo
  • , Atsuhisa Tamura
  • , Mitsuhiro Kamimura
  • , Kazuhiro Sakamoto
  • , Michihiro Yoshimi
  • , Yoshifumi Soejima
  • , Yoshio Tomizawa
  • , Shun Ichi Isa
  • , Minoru Takada
  • , Hideo Saka
  • , Akihito Kubo

Research output: Contribution to journal › Article › peer-review

238   Link opens in a new tab Citations (Scopus)

Fingerprint

Dive into the research topics of 'Randomized phase III trial of erlotinib versus docetaxel as second- Or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and erlotinib lung cancer trial (DELTA)'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science